Abstract: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, and R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.

Abstract: The invention is concerned with novel ingestible cross-linked homopolymers having functional groups consisting of linear or branched amines, of the formula: ##STR1## and their pharmaceutically acceptable salts of the formulae: ##STR2## wherein P represents a hydrophilic, cross-linked and non-digestible homopolymer backbone; R is a hydrogen atom or a lower alkyl radical; X.sup.- is a pharmaceutically acceptable anion; m is an integer varying from 1 to 10 inclusive; and n, o and p are, independently, integers varying from 2 to 12 inclusive. The amine functionalized and cross-linked homopolymers of the invention are highly efficient adsorbents for bile acids and salts and can thus be used for reducing hypercholesterolemia in affected humans.

Abstract: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, and R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.

Abstract: The invention is concerned with a metal ion coordinated polyamine resin in which a non-toxic, pharmaceutically acceptable chelating metal ion is coordinated with a cross-linked and non-digestible polymeric amine selected from the group consisting of: (a) polyamine resins with a hydrophilic backbone, of the formula: ##STR1## wherein P represents a hydrophilic, cross-linked and non-digestible homopolymer backbone, m is an integer varying from 1 to 10 inclusive, and n, o and p are, independently, integers varying from 2 to 12 inclusive; (b) polyamine resins with a hydrophobic backbone, of the formula:P'--[NH(CH.sub.2).sub.n ].sub.m NH.sub.2 (II)wherein P' represents a hydrophobic, cross-linked and non-digestible homopolymer backbone, m is an integer varying from 0 to 6 inclusive and n is an integer varying from 2 to 12 inclusive; and (c) cross-linked copolymers of a polyethylenepolyamine containing from 2 to 6 ethylene units and epichlorohydrin.

Abstract: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, the substituents R.sup.1 and R.sup.2 at position 2 of the dioxane ring have a variety of values defined hereinafter, and R.sup.4 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.

Abstract: The invention describes novel (2-styryl-, 2-naphthyl- and 2-phenethyl-4-o-hydroxyphenyl-1,3-dioxan-5-yl)alkenoic acids and related tetrazoles and sulphonamides, of the formula I wherein Q completes a benzene or pyridine ring, Y is vinylene, Z is carboxy, 1(H)-tetrazol-5-yl or a group of the formula --CO.NHSO.sub.2 R.sup.6, and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, A.sup.1, A.sup.2, n and m have the meanings defined in the specification, and pharmaceutically acceptable salts thereof, for use in conjunction with their pharmaceutical compositions in treating certain pulmonary and/or vascular disorders. The invention also describes various processes and intermediates for the manufacture of the novel compounds.

Abstract: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkanoic and alkenoic acid derivatives of the formula I in which the groups at positions 2, 4 and 5 of the 1,3-dioxane ring have cis-relative stereochemistry, Y is ethylene or vinylene, n is 1-4, Z is hydrogen or hydroxy, and X is a pyridine containing group (as defined hereinafter); and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.

Abstract: The invention concerns novel pharmaceutical compositions containing a 4(Z)-6-(2,4-diphenyl-1,3-dioxan-5-yl)-alkenoic acid which antagonizes one or more of the actions of thromboxane A.sub.2, together with a compound which inhibits the synthesis of thromboxane A.sub.2. The compositios are useful as medicines in treating a variety of diseases or medical conditions in which thromboxane A.sub.2 and/or other prostanoid contractile substances are involved.

Abstract: The invention provides a novel group of 4(Z)-([2,4,5-cis]-2,4-diphenyl-1,3-dioxan-5-yl)hexenoic acids of formula I, wherein X is F, Cl, Br, CF.sub.3, CN, CH.sub.3 O or NO.sub.2 and one of Y and Z is hydrogen or fluoro and the other is hydrogen, and their pharmaceutically acceptable salts; together with their pharmaceutical compositions for use in treating a variety of disease conditions. Also provided are methods for the manufacture of novel compounds. Representative compounds are those in which X is 2-cyano or 2-chloro and Y and Z are both hydrogen.

Abstract: The invention concerns novel N-[4(Z)-2-substituted-6-(4-o-hydroxyphenyl-1,3 dioxan-cis-5-yl)hexenoyl]sulphonamide derivatives of formula I of value as therapeutic agents. Typically R.sup.1 is a branched (3-6C)alkyl, trifluoromethyl or phenyl radical as defined hereinafter and R.sup.2 is alkyl, benzyl or phenyl.The invention also discloses salts of the formula I compounds as well as pharmaceutical compositions containing the compounds and processes for the production of the compounds.

Abstract: The invention describes various novel tetrazole derivatives of the formula I in which R.sup.1 and R.sup.2 are independently hydrogen, trifluoromethyl or (1-6C)alkyl (but R.sup.1 and R.sup.2 is not greater than 6 carbon atoms), or R.sup.1 is optionally substituted phenyl and R.sup.2 is hydrogen, Y is vinylene, n is 1 or 2 and m is 1, 2 or 3, or a pharmaceutically acceptable salt thereof, for use in conjunction with their pharmaceutical compositions in the treatment of various pulmonary and/or vascular disorders. Also described are various processes and intermediates for the manufacture of the novel compounds.

Abstract: The invention describes novel (2-styryl-, 2-naphthyl- and 2-phenethyl-4-o-hydroxyphenyl-1,3-dioxan-5-yl)alkenoic acids and related tetrazoles and sulphonamides, of the formula I wherein Q completes a benzene or pyridine ring, Y is vinylene, Z is carboxy, 1 (H)-tetrazol-5-yl or a group of the formula --CO.NHSO.sub.2 R.sup.6, and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, A.sup.1, A.sup.2, n and m have the meanings defined in the specification, and pharmaceutically acceptable salts thereof, for use in conjunction with their pharmaceutical compositions in treating certain pulmonary and/or vascular disorders. The invention also describes various processes and intermediates for the manufacture of the novel compounds.

Abstract: The invention concerns novel 1,3-dioxane hexenoic aids and related carboxytic acid esters and alkanesulphonamides of the formula I in which X is oxy or thio, R.sup.1 is hydrogen, halogeno, trifluoromethyl, cyano or nitro and R.sup.2 is hydrogen, together with their pharmaceutically acceptable salts. The invention also concerns processes for the production of the novel compounds and pharmaceutical compositions containing the compounds for use in the treatment of various diseases in which thromboxane A.sub.2 (TXA.sub.2) is implicated.

Abstract: The invention concerns the novel racemic and laevorotatory optically active forms of the thromboxane A.sub.2 antagonist 5(Z)-7-([ 2,4,5-cis]-4-o-hydroxyphenyl-2-trifluoromethyl-1,3-dioxan-5-yl)heptenoic acid of formula I, their salts, pharmaceutical compositions, and processes for their manufacture and intermediates therefor. The pharmaceutical agents and their compositions are of value in certain pulmonary and/or vascular disorders.

Abstract: The invention provides a novel group of 4(Z)-([2,4,5-cis]-2,4-diphenyl-1,3-dioxan-5-yl)hexenoic acids of formula I, wherein X is F, Cl, Br, CF.sub.3, CN, CH.sub.3 O or NO.sub.2 and one of Y and Z is hydrogen or fluoro and the other is hydrogen, and their pharmaceutically acceptable salts; together with their pharmaceutical compositions for use in treating a variety of disease conditions. Also provided are methods for the manufacture of novel compounds. Representative compounds are those in which X is 2-cyano or 2-chloro and Y and Z are both hydrogen.

Abstract: Underwater liquid storage tank or facility adapted to hold or temporarily store varying quantities of a liquid having a density less than water. Said liquid can include crude oil and petroleum products. The facility includes means for maintaining the holding space in a full condition by the addition or removal of water. Further included is means to avoid inadvertent pollution of the surrounding water through the unintentional discharge of amounts of the less dense liquid which can be carried by water leaving the tank. Also included is means forming a protective barrier about the liquid holding tank to avoid serious leakage and possible damage to the environment in the event the facility is ruptured by a floating vessel or other object.

Abstract: Underwater liquid storage tank or facility adapted to hold or temporarily store varying quantities of a liquid having a density less than water. Said liquid can include crude oil and petroleum products. The facility includes means for maintaining the holding space in a full condition by the addition or removal of water. Further included is means to avoid inadvertent pollution of the surrounding water through the unintentional discharge of amounts of the less dense liquid which can be carried by water leaving the tank. Also included is means forming a protective barrier about the liquid holding tank to avoid serious leakage and possible damage to the environment in the event the facility is ruptured by a floating vessel or other object.